- Home
- UROY vs CLLS Comparison
UROY vs CLLS Comparison
Compare UROY & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- CLLS
- Stock Information
- Founded
- UROY 2017
- CLLS 1999
- Country
- UROY Canada
- CLLS France
- Employees
- UROY N/A
- CLLS N/A
- Industry
- UROY
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- UROY
- CLLS Health Care
- Exchange
- UROY Nasdaq
- CLLS Nasdaq
- Market Cap
- UROY 294.0M
- CLLS 164.2M
- IPO Year
- UROY N/A
- CLLS 2007
- Fundamental
- Price
- UROY $2.13
- CLLS $1.57
- Analyst Decision
- UROY Strong Buy
- CLLS Buy
- Analyst Count
- UROY 2
- CLLS 3
- Target Price
- UROY $5.60
- CLLS $7.00
- AVG Volume (30 Days)
- UROY 2.4M
- CLLS 59.8K
- Earning Date
- UROY 12-12-2024
- CLLS 11-04-2024
- Dividend Yield
- UROY N/A
- CLLS N/A
- EPS Growth
- UROY 256.61
- CLLS N/A
- EPS
- UROY 0.03
- CLLS N/A
- Revenue
- UROY $27,478,292.00
- CLLS $36,042,000.00
- Revenue This Year
- UROY N/A
- CLLS $271.02
- Revenue Next Year
- UROY $72.53
- CLLS $33.48
- P/E Ratio
- UROY $82.15
- CLLS N/A
- Revenue Growth
- UROY 31.26
- CLLS 46.96
- 52 Week Low
- UROY $1.86
- CLLS $1.53
- 52 Week High
- UROY $3.76
- CLLS $3.55
- Technical
- Relative Strength Index (RSI)
- UROY 31.97
- CLLS 27.91
- Support Level
- UROY $2.42
- CLLS $1.85
- Resistance Level
- UROY $2.70
- CLLS $2.09
- Average True Range (ATR)
- UROY 0.14
- CLLS 0.09
- MACD
- UROY -0.03
- CLLS -0.04
- Stochastic Oscillator
- UROY 10.94
- CLLS 0.00
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.